benzooxazol-2-yl-[1-(3-cyclopentyloxy-4-methoxy-benzyl)-piperidin-4-yl]-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: benzooxazol-2-yl-[1-(3-cyclopentyloxy-4-methoxy-benzyl)-piperidin-4-yl]-amine
• 英文别名: N-(1-(3-(cyclopentyloxy)-4-methoxybenzyl)piperidin-4-yl)benzo[d]oxazol-2-amine；N-[1-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-4-yl]-1,3-benzoxazol-2-amine
• 化学式: C₂₅H₃₁N₃O₃
• 分子量: 421.539
• InChiKey: JVRMWPFNOXAMFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  59.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  benzooxazol-2-yl-piperidin-4-ylamine dihydrobromide 、 3-环戊氧-4-甲氧基苯甲醛 在 sodium cyanoborohydride 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 反应 18.0h， 生成 benzooxazol-2-yl-[1-(3-cyclopentyloxy-4-methoxy-benzyl)-piperidin-4-yl]-amine
  参考文献：
  名称：

  Discovery of the First Nonpeptidic, Small-Molecule, Highly Selective Somatostatin Receptor Subtype 5 Antagonists: A Chemogenomics Approach

  摘要：

  We disclose the first selective, nonpeptidic, small-molecule somatostatin receptor subtype 5 (SST5R) antagonists that were identified by a chemogenomics approach based on the analysis of the homology of amino acids defining the putative consensus drug binding site of SST5R. With this strategy, opioid, histamine, dopamine, and serotonine receptors were identified as the closest neighbors of SST5R. The HI antagonist astemizole was chosen as a seed structure and subsequently transformed into a SST5 receptor antagonist with nanomolar binding affinity devoid of the original target activity.

  DOI：

  10.1021/jm701143p

文献信息

• Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
  申请人：Binggeli Alfred

  公开号：US20060205718A1

  公开（公告）日：2006-09-14

  This invention is concerned with compounds of the formula wherein A, B 1 , B 2 , R 1 , R 2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式的化合物 其中A、B 1 、B 2 、R 1 、R 2 和G如描述和索赔中所定义，并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
• BENZOTHIAZOLE, THIAZOLOPYRIDINE, BENZOOXAZOLE AND OXAZOLOPYRIDINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1858901B1

  公开（公告）日：2008-11-05
• US7645753B2
  申请人：——

  公开号：US7645753B2

  公开（公告）日：2010-01-12
• Discovery of the First Nonpeptidic, Small-Molecule, Highly Selective Somatostatin Receptor Subtype 5 Antagonists: A Chemogenomics Approach
  作者：Rainer E. Martin、Luke G. Green、Wolfgang Guba、Nicole Kratochwil、Andreas Christ

  DOI：10.1021/jm701143p

  日期：2007.12.13

  We disclose the first selective, nonpeptidic, small-molecule somatostatin receptor subtype 5 (SST5R) antagonists that were identified by a chemogenomics approach based on the analysis of the homology of amino acids defining the putative consensus drug binding site of SST5R. With this strategy, opioid, histamine, dopamine, and serotonine receptors were identified as the closest neighbors of SST5R. The HI antagonist astemizole was chosen as a seed structure and subsequently transformed into a SST5 receptor antagonist with nanomolar binding affinity devoid of the original target activity.